Exagen Inc. Common Stock

Day range

$7.05 – $7.59

Open

$7.20

Prev close

$7.27

Volume

191.38K

Market cap

$176.12M

Shares out

24.23M

P/E

—

P/S

2.48

P/B

14.42

P/FCF

—

ROE

-154.9%

ROA

-36.4%

Debt/Equity

2.09

Div yield

0.00%

As of Oct 23, 2026

• Director departureApr 23, 2026

  On April 17, 2026, Ana Hooker notified the Board of Directors (the "Board") of Exagen Inc. (the "Company") of her decision to resign as member of the Board, including all committees thereof, effective April 17, 2026 ("Effective Time"). Ms. Hooker was a member of the Audit Committee and chair of the Nominating and Corporate Governance Committee. Her decision to resign was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Preliminary resultsJan 12, 2026

  On January 11, 2026, Exagen Inc. (the "Company") announced in a press release (the "Press Release") certain select preliminary unaudited financial information and results of operations for the three months and year ended December 31, 2025, based on currently available information.

• Director appointmentJul 17, 2025

  On July 17, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Exagen Inc., the Board appointed, effective as of July 17, 2025, Charles S. McKhann to serve as a Class III director, with an initial term expiring at the Company's 2028 annual meeting of stockholders. In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Compensation Committee of the Board and the Nominating Committee.

• Annual meeting resultsJun 11, 2025

  Exagen Inc. held its 2025 annual meeting of stockholders on June 10, 2025. At the Annual Meeting, the Company's stockholders voted on four proposals. Proposal 1: The Company's stockholders elected the following two Class III directors for a three-year term of office expiring at the Company's 2028 annual meeting of stockholders.

• Public offeringMay 9, 2025

  On May 9, 2025, Exagen Inc. (the "Company") closed its previously announced public offering (the "Public Offering") of 3,350,000 shares of its common stock, par value $0.001 per share (the "Common Stock"), at a public offering price of $5.25 per share (the "Public Offering Price"), pursuant to an underwriting agreement with Canaccord Genuity LLC, as representative of the several underwriters named therein (the "Underwriter").

Days to cover

2.5

Short interest

704.63K

Avg volume

286.37K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
  neutralGlobeNewswire Inc.· Feb 24, 2026
• Exagen Inc. Announces Select Preliminary 2025 Financial Results
  positiveGlobeNewswire Inc.· Jan 11, 2026
• Exagen Inc. to Participate in Fourth Quarter Investor Conferences
  positiveGlobeNewswire Inc.· Nov 11, 2025
• Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
  Zacks Investment Research· Jun 13, 2024
• Time to Play 5 Top-Ranked Stocks With Rising P/E?
  Zacks Investment Research· Jun 10, 2024